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Amniotic ﬂuid stem cells can be expanded without feeder layers and can differentiate into mesenchymal
and hematopoietic lineages. Long-term engraftment has been difﬁcult to achieve after prenatal stem cell
transplantation, mainly because of allogeneic rejection. Autologous cells can be obtained from amniotic
ﬂuid with minimal risk. This review aims to deﬁne the potential of human amniotic ﬂuid stem cells as an
autologous stem cell source for minimal invasive prenatal cell or cell-based gene therapy. We conclude
that amniotic ﬂuid-derived stem cells are an important source of autologous cells that may have prenatal
therapeutic value in cell or cell-based gene therapy in the near future.
Copyright  2014, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
For some life-threatening early-onset congenital diseases, per-
forming in utero therapy may provide an advantage over neonatal
or adult treatment for the following reasons.1
(1) Preventing disease-induced damage prior to birth: The
advantage of prenatal therapy is that pathological damage to
the fetus during prenatal development may be prevented.2
Many severe life-threatening congenital diseases have their
onset while the baby is in utero. Organ damage is often
irreversible, and to add to that, postnatal treatment cannot
improve the quality of life. Any pathological effect maymake
the newborn dependent on medicines for the rest of their
lives and severely handicapped. For example, a fetus with
beta thalassemia major will need lifelong blood transfusions
due to severe anemia.
(2) Targeting stem cell and progenitors: Stem cells and pro-
genitors expand rapidly in utero, making them accessible to
gene transfer, which can produce a large pool of corrected
cells. Compared to adult bone marrow stem cells or periph-
eral blood, fetal stem cells have a much better ability to
differentiate and expand.3ts of interest relevant to this
Gung Memorial Hospital at
e, 5, Fu-Shin Street, Taoyuan
for Gynecologic Endoscopy and Minim(3) Dose scaling: The small size of a fetus is an advantage in
prenatal therapy. The dose of vector or cells used in adult
gene therapy or stem cell transplantation is much higher
than that required during fetal life.4 According to animal
studies, the dosage usually is calculated on a per-kilogram
body mass basis. Production of usable vector or cells is
time consuming and expensive; thus, a lower dose or cell
number is advantageous. A few studies have shown that the
number of cells for in utero transplantation could be reduced
in experiments on mice, sheep, or humans.5e7
(4) Immunological immaturity: Immunological naivety in the
early-gestation fetus has given rise to the concept of fetal
tolerance, the inability to raise an immunological response
against foreign antigens.8
Introduction of a foreign protein or antigen and maintenance of
its expression during gestation leads to the development of
immune tolerance to the foreign protein. This has been
demonstrated to occur in fetal gene therapy experiments in
mice. Waddington et al9 demonstrated a permanent correction
of hemophilia B mice after prenatal gene therapy. The plasma
factor IX antigen remained at around 9%, 13%, and 16% of the
normal level in hemophilia B mice, but was reduced to unde-
tectable levels when the animals were injected postnatally.
Rejection of donor cells plays a critical role in transplantation
and has a major effect on the success rate.10
(5) Finally, for structural congenital abnormalities, repair in
utero may provide a better correction of the defect because
there is less scarring, and the pathological process may be
interrupted. There is evidence of beneﬁt, for example, for in
utero treatment of spina biﬁda.11ally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
S.-W.S. Shaw / Gynecology and Minimally Invasive Therapy 3 (2014) 1e62Prenatal therapy for congenital diseases can be applied in a
variety of ways, using gene therapy, stem cell therapy, or a
combination of the two techniques. Amniotic ﬂuid stem (AFS)
cells are a source of autologous stem cell transplantation. The
minimal invasive prenatal cell therapymodel is discussed in this
review.
Stem cells
Stem cells are essential for the development of any living or-
ganism.12 These cells have the ability to develop and grow during
early life and adulthood; differentiate into different lineages such as
osteogenic, myogenic, chondrogenic, and adipocyte; and self-
renew by cell division. These are the key characteristics that
make stem cells different from other cell types.12,13
Stem cells can be classiﬁed into the following categories ac-
cording to their potency: pluripotent, multipotent, and totipo-
tent.13,14 Totipotency is the ability of all living cells to regenerate
whole new individuals, such as cloning. Pluripotency is the po-
tential of a cell to develop into more than one type of mature cell,
depending on the environment. A pluripotent cell can create all cell
types, except for extra embryonic tissue. Multipotency is the ability
of a cell to develop into a closely related family of cells. For example,
a blood stem cell can develop into different types of blood cells,
such as erythrocytes and leucocytes, but not into any other kinds of
cells. Stem cells can be derived from many different accessible
sources such as bone marrow, peripheral blood, cord blood, cho-
rionic villi, and amniotic ﬂuid (AF).15,16 In addition, stem cells reside
within tissues and organs. Embryonic stem cells (ESCs), mesen-
chymal stem cells (MSCs), endothelial progenitor cells, hemato-
poietic stem cells (HSCs), and AFS cells are a few types of stem cells
that have been studied.17e19
Stem cells are likely to be important in the repair of tissues and
organs, and for the treatment of diseases such as myocardial
infarction, diabetes, and ischemic disease that are associated with
aging.19e21 They may also provide a renewable source of cells for
tissue engineering.22
Stem cells derived from AF
A variety of stem cells can be derived from AF, including MSCs,
cells with hematopoietic potential, and pluripotent cells.
AF is a clear, watery liquid that surrounds a growing fetus within
the amniotic cavity and has a number of roles. The ﬂuid allows the
fetus to grow and move inside the uterus, protects the fetus from
outside injury by cushioning sudden blows or movements, acts as a
vehicle for the exchange of body chemicals with the mother, and is
vital for the development of some organs such as the lungs, in
which inhalation of AF during fetal breathing movements allows
normal lung development. AF contains cells of fetal origin such as
the amnion, skin, and respiratory system.23,24 It is commonly used
in prenatal diagnosis of chromosomal or genetic defects in a
fetus.25e27 Amniocentesis is a well-established and least minimally
invasive procedure in clinical practice. The miscarriage rate has
been reported to be as lowas 1 in 769, when performed by a trained
fetal medicine specialist.28 In humans, amniocentesis is usually
performed after 15 weeks of gestation, because earlier sampling is
associated with abnormalities of limb development.
AF contains stem cells that can differentiate into the three
embryonic layers, including adipogenic, osteogenic, myogenic,
neural, epithelial, and hepatocyte lineages. The cells have both
MSC and HSC differentiation potentials.29 Studies on trans-
planted AFS cells do not report any teratoma formation. In the
past few years, strong evidence has emerged that AF can be used
not only as a diagnostic tool, but also as a potential source oftherapeutic applications for a multitude of disorders.27 AFS cells
are of two types, which are discussed in the following
subsections.
CKitþ AFS cells
The ﬁrst evidence that AF may contain pluripotent stem cells
was provided when Prusa et al30 described the presence of a
distinct subpopulation of proliferating AF cells (0.1e0.5%)
expressing the pluripotency marker octamer binding transcription
factor 4 (Oct4) at both transcriptional and protein levels. Oct4 is a
nuclear transcription factor that plays a critical role in maintaining
the differentiation potential and the self-renewal capacity of
ESCs.31e33 Other than its expression by ESCs, Oct4 is speciﬁcally
expressed by germ cells, where its inactivation results in apoptosis,
and by embryonal carcinoma cells and tumors of germ cell origin,
where it acts as an oncogenic fate determinant.34e37 Although its
role in stem cells of fetal origin has not been elucidated completely,
it has recently been demonstrated that Oct4 is neither expressed
nor required by somatic stem cells or progenitors.38e40
Following the study presented by Prusa et al,30 different groups
conﬁrmed the expressions of Oct4 and its transcriptional targets
(e.g., Rex-1) in AF.41,42 Remarkably, Karlmark et al43 transfected
human AF cells with the green ﬂuorescent protein gene under
either the Oct4 or the Rex-1 promoter, and established that some
AF cells were able to activate these promoters. Several authors
subsequently reported the possibility of harvesting AF cells that
display features of pluripotent stem cells.24,44 Thereafter, the
presence of a cell population that can generate clonal cell lines
capable of differentiating into lineages representative of all three
embryonic germ layers was deﬁnitively demonstrated.45 These
cells, named amniotic ﬂuid stem cells (AFS cells), are characterized
by the expression of the surface antigen c-kit (CD117), the type III
tyrosine kinase receptor of the stem cell factor.46
Pluripotent cells displaying CKitþ have so far been isolated from
the AF of humans and rodents.45 CKit (CD117) is a surface antigen
and a receptor for the stem cell factor.27 CKit is a Type III tyrosine
kinase receptor for the ligand of cytokine stem cell factor; these
receptors locate on the cell membranes of germ cells, HSCs, neu-
roectodermal cells,47 cardiac cells,48 and retinal stem cells.49
Approximately 0.8e1.4% of the cells from human AF possess the
CKitþ surface antigen, and they can be sorted by immunoselection
with magnetic microspheres. CKitþ stem cells from the AF were
named “AFS” cells.45 The expansion of human AFS cells has been
well established with a high population doubling rate, and their
phenotype has been well characterized.24,27,45,50,51
These cells can maintain their potential up to 250 passages
without any change in the telomerase length. However, they do not
show teratoma formation while in vivo injection is performed,
which is the main concern and ethical issue in ESCs.45 Moreover, it
has been shown that AFS cells can easily be transduced without
losing their potential in humans, mice, and sheep.52,53 Rodent and
murine AFS cells have similar characteristics to human AFS cells.
Rodent AFS cells demonstrate growth properties and differentia-
tion potential similar to human AFS cells (in vitro), whereas murine
AFS cells express markers of embryonic and adult stem cell types.45
Finally, freshly isolated AFS cells can generate various hematopoi-
etic lineages both in vitro and in vivo.54 AFS cells have an estimated
doubling time of 36 hours, and no feeder layers are required for the
culture of these cells. The high capacity of self-renewal is impres-
sive, where AFS cells may proliferate over 300 times (exceeding
Hayﬂick’s limit)55 and retain the same karyotypes without devel-
oping chromosomal anueploidies.27
As mentioned previously, the surface antigen CKit (CD117) is
known to be a receptor of the stem cell factor and to play an
Fig. 1. Morphology of amniotic ﬂuid mesenchymal stem cells. The cells display a
uniform spindle-shaped ﬁbroblast-like morphology (image magniﬁcation 40).
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sis.56 Human AFS cells express surface markers of mesenchymal
and/or neural stem cells origin; stage-speciﬁc embryonic antigen
(SSEA)-4, a marker that is usually present in embryonic stem (ES)
cells; and Oct4, a transcription factor.45 AFS cells are positive for a
number of MSC markers, including CD29, CD44, CD73, CD90,
CD105, and vimentin and negative for HSC markers such as CD34,
CD45, and CD133.57,58 Because MSCs are less immunologically
competent than their hematopoietic counterparts,59 human AFS
cells may be good candidates for transplantation, as theymay result
in less transplantation-related rejection. Human AFS cells can
either expand or be induced to differentiate into various cells of the
three embryonic layers, including adipocytes, osteocytes, endo-
thelial cells, hepatocytes, myocytes, and neuronal cells.27,45,57
Importantly, our collaborated group has recently demonstrated
that, when injected into irradiated Rag e/e immunodeﬁcient mice,
murine AFS cells are able to reconstitute the entire bone marrow
and hematopoietic lineages.29 This was the ﬁrst paper showing that
HSC-like characterization could be found in AF cell samples. Table 1
presents a summary of the characteristics of AFS cells and a com-
parison between these and other stem cells types. AFS cells have
ESC-like pluripotent markers, including SSEA-3, SSEA-4, and Tra-1-
60, but AFMSCs or HSCs do not.
Amniotic ﬂuid mesenchymal stem cells
In humans, amniotic ﬂuid mesenchymal stem cells (AFMSCs)
can be obtained easily from the 2nd- and 3rd-trimester AF, where
their percentage has been estimated to be 0.9e1.5%60; in rodents,
these cells can be obtained from the AF collected during the 2nd
week and 3rd week of pregnancy.45
Various protocols have been proposed for their isolation; all are
based on the expansion of unselected populations of AF cells in
serum-rich conditions without feeder layers, allowing cell selection
by culture conditions. The success rate of the isolation of AFMSCs
has been reported to be 100% by different authors.61,62 AFMSCs
grow in a basic medium containing fetal bovine serum (20%).
Importantly, it has been shown that human AFMSCs can also be
cultured in the absence of animal serum, without losing their
properties63; this ﬁnding is a fundamental prerequisite for the
beginning of clinical trials in humans where culture is usually
carried out in a serum-free medium.
Fig. 1 shows the characteristic uniform spindle-shaped ﬁbro-
blast-like morphology of AFMSCs, which is similar to that of other
MSC populations. AFMSCs expand rapidly in culture.61 Human cells
derived from a single 2 mL AF sample can increase in number up toTable 1
Characteristics of different kinds of stem cells.57,58
AFS cells AFMSCs HSCs ESCs
SSEA-3 þ   þ
SSEA-4 þ   þ
Tra-1-60 þ   þ
Tra-1-81    þ
CD73 þ þ 
CD90 þ þ þ
CD117 þ  þ
CD105 þ þ 
CD14   þ
CD34   þ
CD45   þ
MHC I þ þ 
MHC II   þ
AFMSC ¼ amniotic ﬂuid mesenchymal stem cell; AFS ¼ amniotic ﬂuid stem;
ESC ¼ embryonic stem cell; HSC ¼ hematopoietic stem cell; SSEA ¼ stage-speciﬁc
embryonic antigen.180  106 cells within 4 weeks (3 passages) and, as demonstrated
by growth kinetics assays, possess a greater proliferative potential
(average doubling time 25e38 hours) than that of bone marrow-
derived MSCs (average doubling time 30e90 hours).60,64 More-
over, the clonogenic potential of AFMSCs has been shown to exceed
that of MSCs isolated from the bone marrow (86  4.3 colonies vs.
70  5.1 colonies).62 Despite their high proliferation rate, AFMSCs
retain a normal karyotype and do not display tumorigenic potential
even after extensive expansion in culture for over 3 months.60
These cells are positive for CD73, CD90, and CD105, which are
standard MSC markers.
Animal models
The use of animal models is essential in the ﬁeld of clinical
research, particularly when translating therapies to the clinic. An-
imal models can provide knowledge on the safety and efﬁcacy of
drugs, cells, and other treatments. A variety of animal models such
as those involving sheep, macaques, and rodents (mice and rats)
have been used to study stem cell transplantation. Isolated cells
from various sources can be injected into animal models to identify
their target and function in the body.23 The behavior, participation,
and development of transplanted cells can be monitored closely.
The usefulness of each model has limitations, as no animal modelTable 2
Characteristics of experimental animals used in prenatal therapy preclinical studies.1
Species Gestational
length (d)
Placenta
shape
Maternofetal
indigitation
Fetal no.
Human
(3rd trimester)
280 Discoidal Villous 1e2
Human
(1st/2nd trimester)
280 Discoidal Villous 1e2
Primates
(higher):
great apes
240 Discoidal Villous 1e2
Primates
(lower):
galago
130 Diffuse Folded 1e2
Rabbit 31 Discoidal Labyrinthine 5e10
Guinea pig 67 Discoidal Labyrinthine 2e5
Rat 21 Discoidal Labyrinthine 5e10
Mouse 21 Discoidal Labyrinthine 5e10
Sheep 145 Cotyledonary Villous 1e2
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model used to study in utero stem cell transplantation (IUSCT) has
its advantages and disadvantages. Table 2 shows the characteristics
of experimental animals commonly used in prenatal therapy pre-
clinical assessment.
Concept and clinical applications of AF stem cells in pre- and
postnatal autologous transplantation
Stem cells derived from AF could be collected, cultured, differ-
entiated into cells with MSC or HSC potential, and then used for
stem cell therapy applications. The major advantage of AFS cells is
that potential cells can be obtained as early as the 2nd trimester of
gestation, providing a chance/time window for autologous trans-
plantation back into the same fetus. In addition, AFS cells can be
stored for further postnatal use with autologous stem cell origin.
Fig. 2 shows this concept of pre- and postnatal autologous trans-
plantation using human AFS cells.
Preclinical experiments on IUSCT
Fetal mice injected with congenic HSCs maintain stable, long-
term, multilineage chimerism compared with less than 20% of
allogeneic recipients.66 In addition, in mice, early allogeneic fetal
stem cell chimerism may be enhanced by pretreatment of the
allogeneic stem cells with cytokines, although long-term engraft-
ment remains unchanged. This may be due to a host innate
response to class I alloantigens or a lack of strain-speciﬁc stromal
support for the allogeneic transplanted cells.67,68 In addition,
maternal T cells in mice have been shown to cross the placenta and
destroy engrafted allogenic cells.69
Schoeberlein et al70 demonstrated the ﬁrst sheep in utero
transplantation model that compared between autologous and
allogeneic stem cell transplantation. Under ultrasound guidance,
they collected a fetal liver sample and cultured the cells in MSCFig. 2. Concept of in utero and postnatal autologous transplantation using amniotic
ﬂuid stem cells. Amniotic ﬂuid can be collected under ultrasound-guided amniocen-
tesis (1), and cultured in vitro (2). These cells can be transduced with a vector encoding
a therapeutic gene (3) and then the transduced cells expanded in vitro (4). Expanded/
transduced cells can be transplanted back into the same fetus after a few weeks as a
fetal autologous transplantation (5); alternatively, stored stem cells or engineered
tissues can be provided to an affected newborn postnatally (6). Note. From “Clinical
applications of prenatal and postnatal therapy using stem cells retrieved from amniotic
ﬂuid,” by S.W. Shaw, A.L. David, and P. De Coppi, 2011, Current Opinion in Obstetrics and
Gynecology, 23, p. 109e116. Copyright 2011 Lippincott Williams & Wilkins, Inc. Reprinted
with permission.condition. They injected intraperitoneally at 48e64 days of gesta-
tional age back to the donor fetus in the autologous group, and fetal
liver from another animal in the allogeneic group. The autologous
group had a much higher loss rate (73% vs. 29%).
Minimally invasive IUSCT in humans
IUSCT aims to treat congenital disorders in a fetus using cells
capable of self-renewal, which can enhance or substitute the
affected tissues/organs of the fetus. Unlike the in utero gene ther-
apy, there is no viral/vector issue in stem cell transplantation.
Around 50 human cases of in utero stem cell therapy have been
reported using cells from fetal liver or parental CD34þ bone
marrow.54,71 Table 3 shows the four categories of diseases that have
been addressed, including hemoglobinopathies, immunodeﬁ-
ciencies, enzyme storage disease, and osteogenesis imperfecta (OI).
Engraftment has been reported in 10 patients, with several of them
having a benign clinical course.54 Attempts to treat diseases such as
sickle cell disease72 or metabolic storage disorders, for example,
have been unsuccessful, even where a suitably matched donor has
been available.
Successful engraftment has been demonstrated only in cases of
immunodeﬁciencies or OI who received IUSCT.
In OI, allogeneic MSCs sourced from fetal liver were injected into
affected fetuses by the intrahepatic route. Successful engraftment
was observed in two out of ﬁve cases.54 In this case, a female fetus
affected by type III OI received an intraperitoneal injection of MSCs
of the human fetal liver at 26 weeks of gestational age. The donor
cells showed persistent bone marrow engraftment (around 7%) up
to the age of 3 years.17
As mentioned previously, all the cells were donated from allo-
geneic sources rather than being of autologous origin, which might
have resulted in the low engraftment success in congenital diseases
such as sickle cell or metabolic storage disorders where the im-
mune system is relatively intact. Stem cells derived from an
autologous or a syngeneic (identical twin) origin could be a possible
solution for IUSCT.
Clinical applications of AFS cells: postnatal tissue repair
AFS cells have been used in a variety of tissue repair studies. AFS
cells have been cultured and isolated from humans, mice, rats,
rabbits, and sheep. Those cells have shown potential to repair chest
wall injury, cardiac injury, neurologic disorder/injury, lung injury,Table 3
Summary of in utero stem cell transplantation cases in humans.
No. of
cases
No. of cases
demonstrating
engraftment
Cell type of
transplantation
Hemoglobinopathies 22 0 Fetal liver or
parental CD34þ BM
Immunodeﬁciencies 12 8 Fetal liver or
parental CD34þ BM
Enzyme storage disease 7 0 Fetal liver or
parental CD34þ BM
Osteogenesis imperfecta 5 2 Fetal liver MSCs
BM ¼ bone marrow.
Note. From “Fetal stem-cell transplantation,” by E. Tiblad and M. Westgren M, 2008,
Best Practice & Research: Clinical Obstetrics & Gynaecology, 22, p. 189e201 Copyright
200X, Name of Copyright Holder. Reprinted with permission; “Clinical applications of
prenatal and postnatal therapy using stem cells retrieved from amniotic ﬂuid,” by
S.W. Shaw, A.L. David, and P. De Coppi, 2011, Current Opinion in Obstetrics and Gy-
necology, 23, p. 109e116. Copyright 2011 Lippincott Williams & Wilkins, Inc.
Reprinted with permission.
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diaphragmatic hernia repair.29,52,63,73e86 Most of them have
demonstrated the ability to repair tissue in adult or neonate stage.
Only a few studies have investigated the use of AFS cells for
transplantation or tissue repairing prenatally.63,86 AFS cells may
provide a great and potential option for the treatment of congenital
diseases in utero in the near future.
For autologous repair, the tendon was engineered using sheep
mesenchymal amniocytes labeled with the green ﬂuorescent pro-
tein, which was expanded and seeded into a collagen hydrogel. This
was then used to repair a diaphragm defect postnatally after cre-
ation in the donor sheep fetus. Cells that were labeled with the
green ﬂuorescent protein were tracked in the sheep and visualized
after sacriﬁcing the animal. Repair of the diaphragmatic herniawith
the autologous AFMSC-engineered tendon had a lower recurrence
than the repair using the collagen hydrogel alone. The recurrence of
diaphragmatic hernia was signiﬁcantly higher in animals with
acellular grafts than in those with cellular grafts supporting the
autologous approach.75
Several studies have also been conducted to ﬁnd an appro-
priate cell source for the treatment of a wide range of disorders.
For instance, the chondrogenic potential of AFS has been studied
and established in order to carry out the regeneration of a
damaged articular cartilage.87 The feasibility of using ovine bone
marrow MSC as a source of heart valve engineering has been
demonstrated.22 This was supported by the ability of cells to
populate in scaffolds and possess similar biomechanical proper-
ties. Many fetuses with structural defects undergo amniocentesis
for prenatal diagnosis, because of the associated high risk of fetal
aneuploidy. This includes abnormalities such as exomphalos,
congenital diaphragmatic hernia, and major cardiac defects. AFS
cells can be collected either via amniocentesis earlier in gestation
or during cesarean delivery, if there is sufﬁcient time between
their collection and use for organ repair. Much will depend on
the different characteristics of cells collected at different time
points of the gestational age; further research is needed to
explore this.
Therefore, autologous transplantation using AFS cells, as illus-
trated in Fig. 2, can be an ideal treatment strategy in the near future.
These cells could be injected back into the same fetus within few
weeks prior to the disease progression or into newborn afterward if
longer time is needed for tissue engineering. Stem cells derived
from AF are a relatively new source of cells, which although is still
relatively unknown, may have a therapeutic value in various dis-
eases diagnosed prenatally and treated pre- and/or postnatally.References
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